A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
Recruiting · Phase 1 · NCT07258849
Conditions: Rheumatoid Arthritis (RA)
At a glance
- Research payments reported, 2025
- $16,685
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 141
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4213663 (drug), LY4213663 (drug), Placebo (drug), Placebo (drug)
- Dates
- Started 2025-12-02; completion 2028-03
- Results posted
- Not yet
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $16,685 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $16,685
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.